Applications of Transition Metal Catalysis in Drug Discovery and Development

An Industrial Perspective
1. Auflage 2012
ISBN: 978-0-470-63132-4
Verlag: Wiley

Buch, Englisch, 384 Seiten, Format (B × H): 161 mm x 240 mm, Gewicht: 730 g

This book focuses on the drug discovery and development applications of transition metal catalyzed processes, which can efficiently create preclinical and clinical drug candidates as well as marketed drugs.  The authors pay particular attention to the challenges of transitioning academically-developed reactions into scalable industrial processes. Additionally, the book lays the groundwork for how continued development of transition metal catalyzed processes can deliver new drug candidates. This work provides a unique perspective on the applications of transition metal catalysis in drug discovery and development – it is a guide, a historical prospective, a practical compendium, and a source of future direction for the field.

Autoren/Hrsg.

Crawley, Matthew L

Trost, Barry M

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie Industrielle Biotechnologie

Inhaltsverzeichnis

Preface vii

Contributors ix

About the Authors xi

1 Transition Metal Catalysis in the Pharmaceutical Industry 1
Carl A. Busacca, Daniel R. Fandrick, Jinhua J. Song, and Chris H. Senanayake (Boehringer Ingelheim Pharmaceuticals)

2 Selected Applications of Transition Metal-Catalyzed Carbon–Carbon Cross-Coupling Reactions in the Pharmaceutical Industry 25
Hong C. Shen (Roche)

3 Selected Applications of Pd- and Cu-Catalyzed Carbon–Heteroatom Cross-Coupling Reactions in the Pharmaceutical Industry 97
Jingjun Yin (Merck)

4 Asymmetric Cross-Coupling Reactions 165
Vince Yeh (Novartis) and William A. Szabo (Consultant in Drug Development)

5 Metathesis Reactions 215
Oliver R. Thiel (Amgen)

6 Transition Metal-Catalyzed Synthesis of Five- and Six-Membered Heterocycles 257
Cheol K. Chung (Merck) and Matthew L. Crawley (Main Line Health)

7 Oxidative Catalysis 277
Lamont Terrell (GlaxoSmithKline)

8 Industrial Asymmetric Hydrogenation 315
Hans-Ulrich Blaser (Solvias)

Index 243

Über Autor(innen)

MATTHEW L. CRAWLEY, PHD, is the Director of the Community Physician Electronic Medical Records Program at Main Line Health. Previously, he has worked as a medicinal chemist at Pfizer and Wyeth Research. Dr. Crawley is an author of more than twenty publications, and his discoveries have resulted in several patents.
BARRY M. TROST, PHD, is Tamaki Professor of Humanities and Sciences in the Department of Chemistry at Stanford University. Dr. Trost has been elected a Fellow of the American Academy of Sciences and member of the National Academy of Sciences. He has served as chairman of the NIH Medicinal Chemistry Study Section, held over 120 university lectureships, and presented over 260 plenary lectures at national and international meetings.